$SSII

SS Innovations International, Inc.

No enriched coverage for $SSII in the last 7 days.

No SEC Form 4 filings for $SSII in the last 30 days.

Med

SS Innovations (NASDAQ: SSII) files $150M shelf, 5.02M shares registered for resale

SS Innovations International, Inc. (NASDAQ: SSII) has filed an S-3 registration statement to offer up to $150 million worth of securities and register 5,016,500 shares of common stock for resale by existing shareholders. The company will not receive proceeds from the resale of these shares, only if underlying warrants are exercised. This filing includes shares from a recent private placement and shares tied to warrants, with the company's CEO, Dr. Sudhir Srivastava, holding a controlling interest of approximately 55.85% of the voting power.

Gift of 10,000 SS Innovations (SSII) shares by affiliated entity

SS Innovations International, Inc.'s Chairman and CEO, Sudhir Srivastava, reported an indirect transfer of 10,000 common stock shares as a bona fide gift. The shares were held by Sushruta Pvt. Ltd., an entity in which Srivastava holds a controlling interest. Following this transaction, entities associated with Srivastava indirectly hold 109,585,767 shares of SS Innovations common stock, with the transfer classified as a routine personal transfer rather than a market sale.

SS Innovations submits robotic system for FDA clearance

SS Innovations has submitted a 510(k) application to the FDA for its SSi Mantra robotic surgery system, seeking clearance for multiple surgical indications including cardiac procedures. The company aims to introduce a lower-cost, multi-specialty platform to the U.S. market, having already installed 138 systems globally and completed over 7,300 surgeries. This move positions the SSi Mantra to compete with leading robotic surgery systems by offering an affordable option for hospitals and surgeons, particularly for underserved communities.

News on $SSII

SSII news & sentiment — SS Innovations International, Inc. | alphai